Evogene Ltd Stock News

Evogene Ltd. (NASDAQ:EVGN ) Q4 2024 Earnings Conference Call March 6, 2025 9:00 AM ET Company Participants Ofer Haviv - President and CEO Nir Nimrodi - Chairperson of the Board Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's Fourth Quarter Results Conference Call.

Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.

Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel , March 6, 2025 /PRNewswire/ -- Evogene Ltd.

Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel , Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025.

Initial fungicidally active compounds already discovered REHOVOT, Israel , Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.

Evogene Ltd. (NASDAQ:EVGN ) Q3 2024 Earnings Conference Call November 21, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Amit Noam - CEO, Lavie BIO Operator Welcome to Evogene's Third Quarter Results Conference Call.

Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023. In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023.

LAV321demonstrated strong results in its third consecutive year of field trials in Europe REHOVOT, Israel , Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd.